A5059625599- CAR-T cell therapy research
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- CRISPR and Genetic Engineering
- Immune Cell Function and Interaction
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Research and Treatments
- T-cell and B-cell Immunology
- RNA Interference and Gene Delivery
- Cancer Immunotherapy and Biomarkers
- Occupational and environmental lung diseases
- Hemoglobinopathies and Related Disorders
- Pluripotent Stem Cells Research
- Acute Lymphoblastic Leukemia research
- Advancements in Semiconductor Devices and Circuit Design
- Biomedical Ethics and Regulation
- Biosimilars and Bioanalytical Methods
- Nanowire Synthesis and Applications
- Cytomegalovirus and herpesvirus research
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Silicon Carbide Semiconductor Technologies
- Prenatal Screening and Diagnostics
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
2016-2025
Kettering University
2015-2025
Columbia University Irving Medical Center
2025
Cornell University
2002-2024
Moffitt Cancer Center
2018
Tongji University
2016
Tongji Hospital
2016
American Society of Gene Therapy and Cell Therapy
2015-2016
New York Proton Center
2005-2015
Medizinische Hochschule Hannover
2013
CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup patients.
CD19 CAR T cell therapy induces complete remissions in 88% of 16 adult patients with relapsed or refractory acute lymphoblastic leukemia.
Five adults with chemotherapy-refractory B-ALL were induced into molecular remissions after treatment CD19 CAR-targeted T cells.
Following immune attack, solid tumors upregulate coinhibitory ligands that bind to inhibitory receptors on T cells. This adaptive resistance compromises the efficacy of chimeric antigen receptor (CAR) cell therapies, which redirect cells tumors. Here, we investigated whether programmed death-1-mediated (PD-1-mediated) exhaustion affects mesothelin-targeted CAR and explored cell-intrinsic strategies overcome inhibition Using an orthotopic mouse model pleural mesothelioma, determined...
The in vivo function of murine granulocyte-macrophage colony-stimulating factor (GM-CSF) was investigated mice, carrying a null allele the GM-CSF gene, that were generated by gene targeting techniques embryonic stem cells. Although steady-state hematopoiesis unimpaired homozygous mutant animals, all animals developed progressive accumulation surfactant lipids and proteins alveolar space, defining characteristic idiopathic human disorder pulmonary proteinosis. Extensive lymphoid hyperplasia...
Abstract CD19-specific chimeric antigen receptor (CAR) T-cell therapy is highly effective against relapsed or refractory acute lymphoblastic leukemia (ALL), but hindered by neurotoxicity. In 53 adult patients with ALL, we found a significant association of severe neurotoxicity high pretreatment disease burden, higher peak CAR expansion, and early elevations proinflammatory cytokines in blood. Patients had evidence blood–cerebrospinal fluid (CSF) barrier disruption correlating grade without...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here a phase I trial adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA real time from surgically resected PDAC tumours. After surgery, sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), cevumeran (a maximum 20 per patient) and...
Human T cells that are reversibly inhibited upon contact with antigen protect bystander tissues from immune destruction.